[Recommendations for treatment of individuals at risk for hereditary breast and ovarian carcinoma].

Germline mutations in BRCA 1 and BRCA 2 gene have been recognized as hereditary predisposition for breast and ovarian cancer for many years. The optimal clinical management of individuals at risk for hereditary breast and ovarian cancer are not completely defined. Current surveillance options are restricted in their effectiveness as well as limitations of the techniques. Surgical prevention interventions are effective, but may be complicated by physical and psychological morbidity. Genetic testing, which plays a role in defining risk, requires careful pre- and post-test counseling to discuss the limitations of testing itself and available management strategies.